Posted in Antibodies, Assay Kits, Biology Cells, cDNA, Clia Kits, Culture Cells, Devices, DNA, Equipments, Exosomes, Gels, Isotypes, Medium & Serums, NATtrol, Panel, Particles, Reagents, Recombinant Proteins, Ria Kits, RNA, Test Kits
Deciphering the Immunological Phenomenon of Adaptive Natural Killer (NK) Cells and Cytomegalovirus (CMV)
Natural cell killer (NK) plays a significant and vital role in the first defense against infection through their ability to target cells without previous sensitization. They also contributed significantly to the activation and recruitment of default and adaptive immune cells through the production of various cytokines and kemokines. In the context of cytomegalovirus infection (CMV), cells NK and CMV have evolved together side by side to employ several mechanisms to avoid each other. However, during this evolution, the discovery of a subset of NK cells is long-lived with an increase in the effector potential, an increase in the response of antibody dependent and the potential to mediate immune memory has revolutionized the biology of NK cells.
The ability of the virus to print on the NK cell receptor repertoire which results in diverse and very functional expansion of NK cells to this day remains a significant immunological phenomenon that only occurs in the CMV context. Here we review our current understanding of the development of these NK cells, which are commonly referred to as adaptive NK cells and their current roles in transplants, infections, vaccination and cancer immunotherapy to describe the role of CMV complexes in the functional fate of NK cells.
In vitro and vivo characterization of Rhesus cytomegalovirus recombinant containing a complete genome
Cytomegalovirus (CMV) is highly adapted to their host species which results in specific specifications of species. Therefore, in the vivo examination of all aspects of CMV biology using animal models using CMV specifically hosts. Rhesus Macaques (RM) infection with Rhesus CMV (RHCMV) has been designated as a representative model for human infection with HCMV due to evolutionary relationships close to hosts and viruses.
However, the only RHCMV clone that allows genetic modification based on the 68-1 strain that has been passed in fibroblasts for decades which resulted in some genome changes due to network culture adaptation. As a result, 68-1 displays a reduction in viremia in RHCMV naive animals and shedding is limited compared to non-cllatal and low isolates. To overcome this limitation, we use the order of order of the primary RHCMV isolate to build a full length RHCMV (FL) by fixing all mutations that affect the open reading frame (ORFS) in 68-1 bacterial chromosomes (BAC). Adult inoculation, immunocompetent, RHCMV-NAIVE RM with a reconstitution virus produces a significant viremia in the blood similar to RHCMV primary isolates and then causes a high number of virus genome copies on the 14th day after infection.
Instead, the spread of the virus was greatly reduced after the removal of genes was also less at 68-1. Transcript analysis of infected networks is more revealed that genes such as kemokines deleted in 68-1 are one of the most superior viral transcripts both in vitro and in vivo that are consistent with important immunomodulating functions of each protein. We conclude that the FL-RHCMV displays in vitro and in the characteristics of the WildType virus virus when adjusted to genetic modification through the BAC recombineering technique.
Cytomegalovirus mice Virion-Associated Protein R131 and R129 are needed for macrophage and dendritic cell infections
Cytomegalovirus (CMV) establishes persistent latent infections in the host, causing disease in immunocomed patients, transplant receivers, and neonates. CMV infection modified the axis of the host of the host by modulating the expression of kemokin and kemokin receptors and by encoding the homology of the chemokin receptor and putatical kemokin. Virus proteins have a role in cellular signaling, migration, and transformation, and disemination of viruses, tropism, latency and reactivation.
Here, we review the contribution of the Kemokesin encoded by CMV and the kemokin receptors on these processes, and then explain the role of the tropism of the RAT CMV (RCMV) R129 and R131 virus. This homology of Human CMV (HCMV) -Chemines Chokines UL128 and UL130 has a special interest because of their double role as a kemokine and complex members of the pentameric entry, which is needed to enter the type of cell that is important for the transmission and spread of the virus. , The contribution of UL128 and UL130 to accelerate chronic rejection of solid organ transplants is poorly understood, and requires an effective Vivo model system to explain the phenomenon. We show similar molecular entrance requirements for R129 and R131 on mouse cells, as observed for HCMV, and provide evidence that R129 and R131 are part of the complex viral entry needed to enter into macrophages, bone marrow cells.
A hidden threat? Cytomegalovirus infection is associated with the volume of cortical gray material reduced in large depression disorders
The human cytomegalovirus infection (HCMV) is associated with neuropathology in patients with immune disorders and / or inflammatory disease. However, the relationship between the volume of gray material (GMV) and HCMV has never been examined in a large depression disorder (MDD) despite inflammation and disorders of viral immunity on the subset of patients. We tested this relationship in two independent samples consisting of 179 individuals with MDD and 41 healthy controls (HC) (samples 1) and 124 MDD participants and 148 HCS (sample 2). Positive HCMV group (HCMV +) and HCMV negative (HCMV-) in each sample balanced on up to 11 different clinical / demographic variables using reverse probabilities of treatment weights.
GMV 87 regions are measured by freesurfer. There is a major effect of HCMV serostatus but not a diagnosis that is replicated throughout the sample. Relative to the subject of HCMV-, the HCMV + subject in the sample 1 showed a significant volume reduction in six regions (puncorrroved <0.05). GMV reduction from the right supramginal gyrus (standard beta coefficient (SBC) = -0.26) and left fusiform gyrus (SBC = -0.25) in the sample 1 replicated in the sample 2: supramginal gyrus (puncur <0.05, SBC = – 0.32), left gyrus fusiform (PFDR <0.01, SBC = -0.51).
GCG Antibody |
E10-30151 |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
GCG Antibody |
E19-6255 |
EnoGene |
100μg/100μl |
EUR 225 |
Description: Available in various conjugation types. |
GCG Antibody |
E91119 |
EnoGene |
100ul |
EUR 255 |
Description: Available in various conjugation types. |
GCG Antibody |
E310797 |
EnoGene |
200ul |
EUR 275 |
Description: Available in various conjugation types. |
GCG Antibody |
CSB-PA009315KA01HU- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
GCG Antibody |
CSB-PA009315KA01HU-100ul |
Cusabio |
100ul |
EUR 466.8 |
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC;WB:1:500-1:2000, IHC:1:50-1:200 |
GCG Antibody |
1-CSB-PA002654 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat, Monkey. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000 |
GCG Antibody |
1-CSB-PA563307 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100 |
GCG Antibody |
1-CSB-PA254989 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
GCG Antibody |
1-CSB-PA291790 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:5000, IHC:1:25-1:100 |
GCG Antibody |
1-CSB-PA132302 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200 |
GCG Antibody |
1-CSB-PA135172 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100 |
GCG Antibody |
CSB-PA694689- |
Cusabio |
each |
EUR 402 |
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF;WB:1:500-1:3000, IF:1:100-1:500 |
GCG Antibody |
CSB-PA694689-100ul |
Cusabio |
100ul |
EUR 379.2 |
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF;WB:1:500-1:3000, IF:1:100-1:500 |
GCG Antibody |
1-CSB-PA160122 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:10-1:50 |
GCG Antibody |
1-CSB-PA165659 |
Cusabio |
-
Ask for price
-
Ask for price
|
|
|
Description: A polyclonal antibody against GCG. Recognizes GCG from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100 |
GCG Antibody |
abx243116-96tests |
Abbexa |
96 tests |
EUR 287.5 |
GCG Antibody |
MBS7136084-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7136084-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7136085-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7136085-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7132124-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1200 |
GCG Antibody |
MBS7127272-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7127272-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7127273-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7127273-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7127274-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7127274-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7128912-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7128912-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7128913-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7128913-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7128914-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7128914-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7128915-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7128915-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7128916-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7128916-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7128917-005mL |
MyBiosource |
0.05mL |
EUR 190 |
GCG Antibody |
MBS7128917-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1205 |
GCG Antibody |
MBS7116375-005mg |
MyBiosource |
0.05mg |
EUR 150 |
GCG Antibody |
MBS7116375-5x01mg |
MyBiosource |
5x0.1mg |
EUR 845 |
GCG Antibody |
MBS7114823-005mL |
MyBiosource |
0.05mL |
EUR 220 |
GCG Antibody |
MBS7114823-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1350 |
GCG Antibody |
MBS9403697-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1230 |
GCG antibody |
MBS9409763-005mL |
MyBiosource |
0.05mL |
EUR 300 |
GCG antibody |
MBS9409763-5x01mL |
MyBiosource |
5x0.1mL |
EUR 1610 |
GCG Antibody |
MBS8516172-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
GCG Antibody |
MBS8516172-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
GCG Antibody |
MBS8516172-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
GCG Antibody |
MBS8516172-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
GCG Antibody |
MBS8504020-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
GCG Antibody |
MBS8504020-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
GCG Antibody |
MBS8504020-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
GCG Antibody |
MBS8504020-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
GCG Antibody |
MBS850409-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
GCG Antibody |
MBS850409-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
GCG Antibody |
MBS850409-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
GCG Antibody |
MBS850409-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
GCG Antibody |
MBS2521261-006mL |
MyBiosource |
0.06mL |
EUR 180 |
GCG Antibody |
MBS2521261-012mL |
MyBiosource |
0.12mL |
EUR 255 |
GCG Antibody |
MBS2521261-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1715 |
GCG Antibody |
MBS9606914-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1220 |
GCG Antibody |
C0206-100ul |
Assay Biotech |
100μl |
EUR 217 |
Description: GCG Rabbit Polyclonal Antibody |
GCG Antibody |
C0206-50ul |
Assay Biotech |
50μl |
EUR 143.5 |
Description: GCG Rabbit Polyclonal Antibody |
Glucagon (GCG) Antibody |
abx117036-100ug |
Abbexa |
100 ug |
EUR 560.4 |
|
Glucagon (GCG) Antibody |
abx032840-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Glucagon (GCG) Antibody |
abx032840-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Glucagon (GCG) Antibody |
abx032992-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Glucagon (GCG) Antibody |
abx032992-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Glucagon (GCG) Antibody |
abx010836-100ug |
Abbexa |
100 ug |
EUR 526.8 |
|
Glucagon (GCG) Antibody |
abx011863-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
Glucagon (GCG) Antibody |
20-abx013090 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ug
- 10 ug
- 200 ug
- 20 ug
- 300 µg
|
|
Glucagon (GCG) Antibody |
abx025306-100ul |
Abbexa |
100 ul |
EUR 627.6 |
|
Glucagon (GCG) Antibody |
abx025307-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
Glucagon (GCG) Antibody |
abx025307-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
Glucagon (GCG) Antibody |
20-abx009229 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
abx022872-1ml |
Abbexa |
1 ml |
EUR 886.8 |
|
Glucagon (GCG) Antibody |
20-abx001034 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
-
Ask for price
|
- 100 ul
- 200 ul
- 20 ul
- 50 ul
|
|
Glucagon (GCG) Antibody |
abx233496-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
Glucagon (GCG) Antibody |
20-abx213670 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx213854 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx213855 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx214483 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx214484 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
abx332258-100ul |
Abbexa |
100 ul |
EUR 510 |
|
Glucagon (GCG) Antibody |
20-abx330081 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx241651 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx241652 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx339306 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
20-abx339307 |
Abbexa |
-
Ask for price
-
Ask for price
|
|
|
Glucagon (GCG) Antibody |
abx117036-100g |
Abbexa |
100 µg |
EUR 450 |
Glucagon (GCG) Antibody |
abx213670-100l |
Abbexa |
100 µl |
EUR 250 |
Glucagon (GCG) Antibody |
abx213854-100l |
Abbexa |
100 µl |
EUR 250 |
Glucagon (GCG) Antibody |
abx213855-100l |
Abbexa |
100 µl |
EUR 250 |
Glucagon (GCG) Antibody |
abx032840-400l |
Abbexa |
400 µl |
EUR 518.75 |
Glucagon (GCG) Antibody |
abx032992-400l |
Abbexa |
400 µl |
EUR 518.75 |
Glucagon (GCG) Antibody |
abx025307-400l |
Abbexa |
400 µl |
EUR 518.75 |
Glucagon (GCG) Antibody |
abx241651-96tests |
Abbexa |
96 tests |
EUR 250 |
Glucagon (GCG) Antibody |
abx241652-96tests |
Abbexa |
96 tests |
EUR 250 |
Glucagon (GCG) Antibody |
abx214483-100tests |
Abbexa |
100 tests |
EUR 350 |
Glucagon (GCG) Antibody |
abx214483-200tests |
Abbexa |
200 tests |
Ask for price |
Glucagon (GCG) Antibody |
abx214483-20tests |
Abbexa |
20 tests |
EUR 250 |
Glucagon (GCG) Antibody |
abx214484-100tests |
Abbexa |
100 tests |
EUR 350 |
Glucagon (GCG) Antibody |
abx214484-200tests |
Abbexa |
200 tests |
Ask for price |
Glucagon (GCG) Antibody |
abx214484-20tests |
Abbexa |
20 tests |
EUR 250 |
Glucagon (GCG) Antibody |
abx233496-100g |
Abbexa |
100 µg |
EUR 350 |
Glucagon (GCG) Antibody |
abx339306-100g |
Abbexa |
100 µg |
Ask for price |
Glucagon (GCG) Antibody |
abx339306-20g |
Abbexa |
20 µg |
EUR 250 |
Glucagon (GCG) Antibody |
abx339306-50g |
Abbexa |
50 µg |
EUR 350 |
Glucagon (GCG) Antibody |
abx339307-100g |
Abbexa |
100 µg |
Ask for price |
Glucagon (GCG) Antibody |
abx339307-20g |
Abbexa |
20 µg |
EUR 250 |
Glucagon (GCG) Antibody |
abx339307-50g |
Abbexa |
50 µg |
EUR 350 |
Glucagon (GCG) Antibody |
abx330081-100g |
Abbexa |
100 µg |
Ask for price |
Glucagon (GCG) Antibody |
abx330081-20g |
Abbexa |
20 µg |
EUR 187.5 |
Glucagon (GCG) Antibody |
abx330081-50g |
Abbexa |
50 µg |
EUR 250 |
Glucagon (GCG) Antibody |
abx013090-100g |
Abbexa |
100 µg |
EUR 62.5 |
Posthoc test revealed that the HCMV effect was driven by the difference between HCMV + and HCMV-MDD subgroups. IgG level HCMV, a substitute marker of viral activity, correlates with GMV in the left fusiform gyrus (r = -0.19, punchortrict = 0.049) and right supramarginal gyrus (r = -0.19, punchvv + group samples 1. Can be imagined, HCMV infection might be The source of neuropathology that can be treated in vulnerable MDD patients.